Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Breaking News & Live Updates
Jim Cramer's Assessment of D-Wave Quantum: A Promising Yet Speculative Venture

Jim Cramer, a prominent financial analyst, has cast a spotlight on D-Wave Quantum Inc. (QBTS), a company at the forefront of quantum computing. He described D-Wave as a 'science project,' acknowledging both its experimental nature and its inherent potential. This assessment came during a discussion about the tech market's volatile speculative segment, particularly in response to a caller's query about D-Wave's rebound prospects.
Highlighting the inherent risks and rewards in this cutting-edge sector, Cramer elaborated on D-Wave's recent stock performance, noting its significant fluctuations. After a climb from $18 to almost $47 by mid-October, the stock experienced a nearly 40% decline, settling below $30. He pointed out that while the company's third-quarter earnings exceeded forecasts, its revenue of $3.7 million underscores the nascent stage of quantum computing technology. Despite these challenges, D-Wave's stock showed a brief rally post-earnings, though it concluded the week with a notable dip, mirroring the broader struggles within the speculative tech market.
D-Wave Quantum Inc. is dedicated to developing advanced quantum computing systems, offering solutions such as Advantage quantum computers, Ocean developer tools, and Leap cloud and hybrid solver services. The company's journey reflects the dynamic and often unpredictable nature of investing in groundbreaking technological advancements. For investors intrigued by the future of computing, D-Wave represents a venture into a field ripe with innovation, where long-term vision may yield substantial returns, albeit with the understanding of its current developmental phase.

Co-author of "Your Money or Your Life," a classic on financial independence and mindful spending.
Other Articles
Jim Cramer's Skepticism on Newsmax (NMAX) Amidst Financial Challenges
Renowned financial commentator Jim Cramer has expressed a pessimistic outlook on Newsmax (NMAX), citing the company's financial losses. He categorizes NMAX as a 'meme stock,' indicating its value is heavily influenced by social media trends rather than traditional market fundamentals. Cramer advises caution against investing in companies currently experiencing financial deficits, suggesting that such ventures often lead to unfavorable outcomes for investors.
By Mr. Money MustacheBofA Adjusts Pfizer's Price Target Amidst Legal and Clinical Developments
Bank of America has revised its price target for Pfizer (PFE) from $27 to $26, maintaining a Neutral rating. This adjustment follows a review of large-cap pharmaceutical and biopharmaceutical coverage. Recent events include a Belgian court order for Poland and Romania to purchase €1.9 billion in COVID-19 vaccines from Pfizer and promising Phase 3 trial results for its Lyme disease vaccine candidate.
By Chika UwazieAllogene Therapeutics: Analysts Predict Over 180% Growth Potential
Analysts are highly optimistic about Allogene Therapeutics (ALLO), with a significant majority issuing 'Buy' ratings. A consensus price target of $7.50 suggests an impressive upside of over 186%. This positive sentiment follows promising developments in their ALPHA3 study and a strong financial position, extending their operational runway into 2028.
By Natalie Pace